Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioLineRx Ltd. (BLRX : NSDQ)

• Company Description    Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $3.06 Daily Weekly Monthly 20 Day Moving Average: 103,888 shares Shares Outstanding: 4.35 (millions) Market Capitalization: $13.32 (millions) Beta: 1.42 52 Week High: $7.77 52 Week Low: $2.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 33.04% 26.54% 12 Week 6.25% -1.78% Year To Date 10.47% -5.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HAMA-AYAN STREET MODI-IN TECHNOLOGY PARK - MODI-IN,L3 7177871 ISR ph: 972-2548-9100 fax: 972-8642-9101 ir@biolinerx.com http://www.biolinerx.com

• General Corporate Information    Officers Philip A. Serlin - Chief Executive Officer Aharon Schwartz - Chairman Mali Zeevi - Chief Financial Officer Raphael Hofstein - Director B.J. Bormann - Director Peer Information BioLineRx Ltd. (GSAC) BioLineRx Ltd. (CASIF) BioLineRx Ltd. (ALCD.) BioLineRx Ltd. (OMNN) BioLineRx Ltd. (CGPI.) BioLineRx Ltd. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09071M304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/27/26 Share - Related Items Shares Outstanding: 4.35 Most Recent Split Date: 1.00 (0.03:1) Beta: 1.42 Market Capitalization: $13.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.57 Price/Cash Flow: - Price / Sales: 11.28 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -54.55% Sales Growth vs. Year Ago Period: -98.35% vs. Previous Quarter: -54.57% ROE 03/31/26 - - 12/31/25 - -5.61 09/30/25 - -16.11 ROA 03/31/26 - - 12/31/25 - -2.81 09/30/25 - -7.20 Current Ratio 03/31/26 - - 12/31/25 - 1.95 09/30/25 - 2.09 Quick Ratio 03/31/26 - - 12/31/25 - 1.78 09/30/25 - 1.93 Operating Margin 03/31/26 - - 12/31/25 - -99.58 09/30/25 - -23.38 Net Margin 03/31/26 - - 12/31/25 - -99.58 09/30/25 - -23.38 Pre-Tax Margin 03/31/26 - - 12/31/25 - -171.70 09/30/25 - -23.38 Book Value 03/31/26 - - 12/31/25 - 5.36 09/30/25 - 4.49 Inventory Turnover 03/31/26 - - 12/31/25 - 0.09 09/30/25 - 2.19 Debt-to-Equity 03/31/26 - - 12/31/25 - 0.19 09/30/25 - 0.29 Debt-to-Capital 03/31/26 - - 12/31/25 - 16.04 09/30/25 - 22.28

Powered by Zacks Investment Research ©